SYNERGY™ Continues to Lead in Complex Patients
SYNERGY BP-DES was intentionally designed with a fast-absorbing polymer for early healing. The latest clinical evidence from the SENIOR Trial and EVOLVE Short DAPT Trial demonstrated excellent results with the SYNERGY BP-DES. EVOLVE Short DAPT reported 3-month data in high bleeding-risk patients and reported extremely favorable ischemic outcomes through 3 months: Cardiac Death: 1.2% MI: 1.4%; TLR 0.3%; Definite/probable ST: 0.3%.
In addition, 2-year data from the SENIOR Trial was reported and continued to provide meaningful evidence on under-represented senior patient population. Key highlights include:
Leading the Fight Against Calcium
Boston Scientific is driving meaningful innovation in the treatment of complex patients, as witnessed during hands-on training with the newly-approved ROTAPRO and the release of compelling new data.
From hands-on training within the Interactive Training Pavilion and extensive usage during live cases to the release of the PREPARE-CALC trial results, which showed rotational atherectomy and was safe and effective for vessel preparation in severe calcium, the message is clear: Boston Scientific offers the breadth and depth needed to help you master the complex.
Contact your sales representative today to learn more about Boston Scientific’s advancements in calcium management and vessel prep.
Class Effect Among Non-Hyperemic Pressure Ratios (NHPR)
Will New HD IVUS Drive Imaging Utilization?
LOTUS™ Valve Data Highlights
Results from the two-year REPRISE III data, the first head-to-head TAVR IDE trial comparing the LOTUS valve to the Evolut R/CoreValve, showed that LOTUS valve patients experienced fewer disabling strokes, fewer repeat procedures, more improvements in NYHA class, and continued best-in-class PVL rates with 86.4% none/trace.
Five-year outcomes from REPRISE II, a prospective, multi-center trial of 120 patients treated with the LOTUS valve, demonstrated good hemodynamic results, minimal paravalvular leak, and durable improvement in NYHA classification, with a favorable safety profile.
In an analysis of PVL and 2-year outcomes in the RESPOND study, significant predictors of mild or greater PVL at discharge included a history of cerebrovascular accidents and history of renal failure. All-cause mortality, cardiovascular mortality, and hospitalization were numerically higher in patients with PVL as well.
EWOLUTION Two-Year data on Single Antiplatelet/No Therapy Subgroup Analysis
Following the conclusion of the
This reduction in bleeding is consistent with the reduction in bleeding seen in the PROTECT AF and PREVAIL
Contact your sales representative today to learn more about Boston Scientific’s advancements in left atrial appendage therapy.